1 / 3

AGENT III: 12 week results

AGENT III: 12 week results. 415 patients with CCS Class 2-4 angina not in need of urgent revascularization. Ad5FGF-4 gene Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4). Placebo. Low-dose. High-dose. Primary Endpoint:

marshall-jaidyn
Download Presentation

AGENT III: 12 week results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AGENT III: 12 week results 415 patients with CCS Class 2-4 angina not in need of urgent revascularization Ad5FGF-4 gene Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4) Placebo Low-dose High-dose • Primary Endpoint: • Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year. Secondary Endpoints: • Time to number of patients with coronary events and death at 12 months • Time to ST depression, angina, and quality of life parameters Presented at TCT 2004

  2. AGENT III Trial: 12 week results Mean change in exercise duration from baseline to 12 weeks p=ns • The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline seconds TCT 2004

  3. AGENT III: 12-week results • 415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board • The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline. TCT 2004

More Related